GenVec, Inc.
(NASDAQ : GNVC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -1.61%91.181.9%$1206.46m
JNJJohnson & Johnson -1.73%146.180.7%$1042.23m
BMYBristol-Myers Squibb Co. 1.30%60.501.0%$1038.33m
MRKMerck & Co., Inc. -1.61%79.420.7%$826.64m
PFEPfizer Inc. -7.54%35.310.9%$791.74m
LLYEli Lilly & Co. -0.35%152.421.1%$502.41m
AZNAstraZeneca Plc 0.40%54.821.2%$281.02m
NVSNovartis AG -1.29%86.300.2%$152.98m
GSKGlaxoSmithKline Plc -0.36%41.770.2%$138.43m
NVONovo Nordisk A/S -0.49%65.620.1%$91.33m
SNYSanofi 0.71%49.460.2%$75.86m
RGENRepligen Corp. 0.42%131.527.1%$69.65m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.82%64.230.0%$49.08m
TPTXTurning Point Therapeutics, Inc. -0.59%68.840.0%$40.23m
ARCTArcturus Therapeutics Holdings, Inc. 0.95%39.310.0%$37.51m

Company Profile

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).